OHIO DEPARTMENT OF MEDICAID
Pharmacy & Therapeutics Committee

Public attendees will need to register at:
https://attendee.gotowebinar.com/register/6996645897747704335

After registering, you will receive an email containing information about joining the webinar.

January 13th, 2021
10:00 A.M.

AGENDA

I. Call to Order
II. Introductions
III. Approval of September 30, 2020 Meeting Minutes
IV. Administrative Matters
   A. Conflict of Interest Statements
V. Department of Medicaid Update
VI. Interested Party Presentations
VII. Unified Preferred Drug List (UPDL) Proposals
   A. Central Nervous System (CNS) Agents: Anticonvulsants
      • Fintepla (fenfluramine HCl solution), Zogenix, Inc.
   B. Central Nervous System (CNS) Agents: Multiple Sclerosis
      • Bafiertam (monomethyl fumarate capsule), Banner Life Sciences LLC
      • Kesimpta (ofatumumab injection), Novartis
   C. Central Nervous System (CNS) Agents: Parkinson's Agents
      • Ongentys (opicapone capsule), Neurocrine Biosciences, Inc.
   D. Endocrine Agents: Diabetes – Insulin
      • Semglee (insulin glargine injection), Mylan
   E. Gastrointestinal Agents: Ulcerative Colitis Agents
      • Ortikos ER (budesonide capsule), Ferring Pharmaceuticals Inc
   F. Infectious Disease Agents: Antivirals – HIV
      • Rukobia ER (fostemsavir tablet), ViiV Healthcare Company
   G. Respiratory Agents: Inhaled Agents
      • Airduo Digihaler (fluticasone and salmeterol), Teva Respiratory, LLC
      • Armonair Digihaler (fluticasone propionate), Teva Respiratory, LLC
      • Breztri™ (budesonide, glycopyrrolate and formoterol), AstraZeneca Pharmaceuticals LP
VIII. Other Business
IX. 2021 Meeting Dates
   A. Quarter 2 – Wednesday, April 14, 2021
   B. Quarter 3 – Wednesday, July 14, 2021
   C. Quarter 4 – Wednesday, October 6, 2021
X. Adjournment